Ebola prevention after high-risk contact
Part of Infections clinical trials.
This trial tests an experimental treatment to prevent Ebola infection in people who have had close contact with someone infected with Ebola within the last 5 days. If you've been in a high-risk situation, joining this trial could help protect you and others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a high-risk contact with someone who has Ebola in the last 5 days.
- You do not have any symptoms of Ebola (like fever, vomiting, or bleeding).
- You have not had an Ebola vaccine (Ervebo or others) in the past 5 years.
- You have not been diagnosed with Ebola in the past 5 years.
- You are not allergic to any of the study drugs or their ingredients.
- You are not currently in another Ebola treatment or vaccine trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares Ebola vaccine immune responses when one Ebola treatment (Inmazeb) is given, then a vaccine (Ervebo) is given later. The goal is to see how the delay in timing changes your body’s immune response.
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
This study tests whether it is safe and effective to give an Ebola vaccine at the same time as a COVID-19 booster shot. It may help find a way to protect against both diseases with fewer clinic visits.
This trial tests an Ebola vaccine in healthy people from local communities to see how it works and how safe it is. You may be able to join if you meet age, health, and vaccination/medication rules and can follow pregnancy-prevention and consent requirements.
This study tests a new mRNA vaccine (mRNA-1469) to prevent Ebola-Bundibugyo virus disease. It is for healthy adults to see if the vaccine is safe and produces an immune response.
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
Hear when a new Ebola Virus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.